


Medtronic

Sphere-360™

pulsed field ablation catheter

Cost savings in AF compared with the pentaspline PFA catheter in the UK¹.



Background

- Technological advancements in atrial fibrillation (AF) ablation have greatly improved procedural safety and efficacy. Pulsed field ablation (PFA) offers the potential for precise myocardial ablation with minimal collateral damage.
- Multiple PFA catheters are currently available, each differing in design and energy delivery. Sphere-360™ pulsed field ablation catheter is a rotation free PFA catheter fully integrated with the Affera™ mapping and ablation system. It streamlines AF treatment and has demonstrated high pulmonary vein lesion durability (98% per vein), predictability, and offers easily reproducible workflow for consistent results across operators².
- As PFA adoption grows, understanding the economic impact of each system becomes increasingly important.

Objective

To evaluate the economic implications of the Sphere-360™ pulsed field ablation catheter compared to the pentaspline catheter for the treatment of paroxysmal AF from the NHS perspective.


Methods

- The economic analysis was based on arrhythmia recurrence, repeat ablations and safety rates. In the absence of head-to-head studies, matching-adjusted indirect comparison (MAIC) was implemented to compare efficacy outcomes from the first-in-human studies of both the Sphere-360™² PFA catheter (NCT05144503, NCT05115214) and the pentaspline³ PFA catheter (NCT03700385, NCT03714178, NCT04170608). MAIC analysis was done in both the total (Sphere-360™ catheter: N=100, pentaspline catheter N=121) and optimized cohorts (Sphere-360™ catheter: N=50, pentaspline catheter N=49).
- A cost comparison based on these MAIC results was performed with a one-year time horizon. One of the studies reported zero safety event rates², and given MAIC cannot be completed with zero event rates, unadjusted safety rates were used for the cost analysis. For repeat ablations, the relative difference in repeat ablation rates derived from the MAIC analysis was applied to the rate reported in the National Institute for Health and Care Excellence (NICE) AF guidelines (NG196)⁴. Repeat ablations were assumed to be performed using a radiofrequency (RF) catheter, with associated safety event rates sourced from NG196.
- Cost estimates for safety events were sourced from NG196 and inflated to 2024 values. Ablation procedure costs were based on the 2023/24 NHS National Cost Collection day-case unit price. Catheter costs were derived from an NHS real-world study.⁵

Results

- The results of this study show that ablation with the Sphere-360™ PFA catheter for the treatment of paroxysmal AF is cost saving compared with the pentaspline catheter in the UK.
- Cost savings with Sphere-360™ PFA catheter were £1,016 in the total cohorts and £685 in the PULSE3/Optimized cohorts.
- Key driver of the results was the efficacy of the catheters, arrhythmia recurrence and repeat ablations.
- In all scenarios ablation with Sphere-360™ PFA catheter remained cost-saving.

Average 1 year per patient cost savings



Conclusion

Sphere-360™ PFA catheter is cost-saving compared to the pentaspline PFA catheter for the treatment of paroxysmal AF patients, from the UK NHS perspective.

References:

1. Ahsan et al. Economic evaluation of two pulsed field ablation systems, a conformable large-lattice catheter versus a pentaspline catheter, for the treatment of paroxysmal atrial fibrillation. Presented at EHRA 2026 Paris. <https://esc365.escardio.org/Ehra-congress/speakers/1413050>.
2. Reddy VY, Peichl P, Kautzner J, et al. One-year outcomes of a conformable single-shot pulsed-field ablation catheter for the treatment of paroxysmal atrial fibrillation. Heart Rhythm 2025; 22(10): 2551-61.
3. Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. Clinical Electrophysiology 2021; 7(5): 614-27.
4. NICE guideline NG196 (atrial fibrillation: diagnosis and management). <https://www.nice.org.uk/guidance/ng196/evidence/full-guideline-pdf-9081927326>.
5. Calvert P. et al. Cost, Efficiency and Outcomes of Pulsed Field Ablation versus Thermal Ablation for Atrial Fibrillation: A Real-World Study. Heart Rhythm. 2024 May 1;21(9).

Medtronic

Europe
Medtronic International Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
www.medtronic.eu
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00

medtronic.eu

This material should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).

Please note that the intended use of a product may vary depending on geographical approvals.

See the device manual(s) for detailed information regarding the intended use, the (implant) procedure, indications, contraindications, warnings, precautions, and potential adverse events.

For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI.

If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com.

Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

Medtronic products placed on European markets comply with EU and UK legislation (if applicable) on medical devices.

For any further information, contact your local Medtronic representative and/or consult Medtronic's websites.

Medtronic medical devices marketed in Spain are in compliance with the Spanish legislation in force.

CE-CV-2600090 © Medtronic 2026. All rights reserved. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. *Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.